checkAd
    Startseite > Aktien > Allogene Therapeutics > Nachrichten
    Allogene Therapeutics Aktie
    2,8900
     
    USD
    +1,23 %
    +0,0350 USD
    Letzter Kurs 26.04.24 Nasdaq
    2,8700
     
    USD
    61.400 STK
    Geldkurs 26.04.24
    2,8800
     
    USD
    900 STK
    Briefkurs 26.04.24
    ISIN: US0197701065 · WKN: A2N6WN · SYM: ALLO · USA

    Neueste Nachrichten

    Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
    26.04.24 · globenewswire · Allogene Therapeutics
    Allogene Therapeutics Announces Q2 Investor Conference Participation
    09.04.24 · globenewswire · Allogene Therapeutics
    Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
    14.03.24 · globenewswire · Allogene Therapeutics
    Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease
    12.03.24 · globenewswire · Allogene Therapeutics
    Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update
    05.03.24 · globenewswire · Allogene Therapeutics
    Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference
    28.02.24 · globenewswire · Allogene Therapeutics
    Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia
    16.02.24 · globenewswire · Allogene Therapeutics
    Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
    16.01.24 · globenewswire · Allogene Therapeutics
    Aktien New York: Anleger nach US-Wirtschaftsdaten hin- und hergerissen
    05.01.24 · dpa-AFX · Ansys
    ROUNDUP/Aktien New York: Trübe Stimmung im Servicesektor wirkt positiv
    05.01.24 · dpa-AFX · Constellation Brands (A)
    Aktien New York Ausblick: Schwächer erwartet nach Arbeitsmarktbericht
    05.01.24 · dpa-AFX · Exxon Mobil
    Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma
    04.01.24 · globenewswire · Allogene Therapeutics